Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Circulation

• Publication date

  2008-12-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.108.772665PMID 19029469
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

  2009cited by this paper
• Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

  2008cited by this paper
• Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

  2007cited by this paper
• Increased intima–media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension

  2007cited by this paper
• Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.

  2007cited by this paper
• Design and Rationale of the ARBITER 6 Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)

  2007cited by this paper
• Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*

  2007cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Effect of torcetrapib on the progression of coronary atherosclerosis.

  2007cited by this paper
• Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

  2007cited by this paper
• The failure of torcetrapib: was it the molecule or the mechanism?

  2006cited by this paper
• Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.

  2006cited by this paper
• Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension.

  2006cited by this paper
• Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.

  2006cited by this paper
• The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3*

  2006cited by this paper
• Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actions⃞

  2006cited by this paper
• Role of the renin–angiotensin–aldosterone system in vascular remodeling and inflammation: a clinical review

  2006cited by this paper
• Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.

  2006cited by this paper
• Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.

  2005cited by this paper
• Serum aldosterone and the incidence of hypertension in nonhypertensive persons.

  2004cited by this paper
• Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins

  2004cited by this paper
• Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib

  2004cited by this paper
• Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

  2004cited by this paper
• Six-Year Effect of Combined Vitamin C and E Supplementation on Atherosclerotic Progression: The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study

  2003cited by this paper
• Scavenger receptor class BI and selective cholesteryl ester uptake: partners in the regulation of steroidogenesis.

  2002cited by this paper
• Vascular inflammation and the renin-angiotensin system.

  2002cited by this paper
• ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness

  2002cited by this paper
• Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS)

  2001cited by this paper
• 1996 Remington lecture: modeling multivariate longitudinal data that are incomplete.

  1999cited by this paper
• Analysis strategies for serial multivariate ultrasonographic data that are incomplete.

  1992cited by this paper
• High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

  1977cited by this paper

• ActivityDiff: A diffusion model with Positive and Negative Activity Guidance for De Novo Drug Design

  2025cites this paper
• Atherosclerotic plaque stabilization and regression: a review of clinical evidence

  2024cites this paper
• Enhancing Wound Healing and Anti-Inflammatory Effects by Combination of CIGB-258 and Apolipoprotein A-I against Carboxymethyllysine Toxicity in Zebrafish: Insights into Structural Stabilization and Antioxidant Properties

  2024cites this paper
• A new risk factor for coronary artery disease can be detected by an ApoA1 mAb-based assay.

  2023cites this paper
• Structure-based mechanism and inhibition of cholesteryl ester transfer protein

  2023cites this paper
• ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future

  2022cites this paper
• Biomarkers

  2021cites this paper
• Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis.

  2019cites this paper
• Lipid Disorders and Familial Hypercholesterolaemia

  2019cites this paper
• Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials.

  2019cites this paper
• Title: Traditional Risk Factors are Causally Related to Carotid Intima-Media Thickness Progression: Inferences from Observational Cohort Studies and Interventional Trials. Running title: Vascular risk factors and C-IMT progression 2 Traditional Risk Factors are Causally Related to Carotid Intima-Med

  2019cites this paper
• Non-coding RNAs in lipid metabolism.

  2019cites this paper
• Key Human Blood Cells Genes Involved in Atherogenesis and Metabolism of High Density Lipoproteins

  2018cites this paper
• Harnessing the Power of Proteomics to Assess Drug Safety and Guide Clinical Trials

  2018cites this paper
• Key Human Blood Cells Genes Involved in Atherogenesis and Metabolism of High Density Lipoproteins

  2018cites this paper
• An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial.

  2017cites this paper
• 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature.

  2017cites this paper
• Increasing HDL-C levels with medication: current perspectives

  2017cites this paper
• Case Histories: Anacetrapib

  2017cites this paper
• The role of the mineralocorticoid receptor in the vasculature

  2017cites this paper
• Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering

  2016cites this paper
• Lipids and apolipoproteins in cardiovascular disease

  2016cites this paper
• Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation

  2016cites this paper
• Aldosterone and type 2 diabetes mellitus

  2016cites this paper
• „Residuales Risiko“: Wie wichtig sind High-Density-Lipoproteine und Triglyzeride?

  2016cites this paper
• Cardiovascular Safety in Drug Development

  2016cites this paper
• Torcetrapib and Dalcetrapib Safety: Relevance of Preclinical In Vitro and In Vivo Models

  2015cites this paper
• Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol: Where Do These Agents Stand in the Approval Process?

  2015cites this paper
• Clinical Feasibility and Monitoring of the Effects of Anti-inflammatory Therapy in Atherosclerosis

  2015cites this paper
• Cell the Atherosclerotic Plaque

  2015cites this paper
• Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics

  2015cites this paper
• Contemporary and Novel Therapeutic Options for Hypertriglyceridemia.

  2015cites this paper
• Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.

  2015cites this paper
• Recent advances in pharmacotherapy for hypertriglyceridemia.

  2014cites this paper
• Future of cholesteryl ester transfer protein inhibitors.

  2014cites this paper
• High density lipoprotein from patients with valvular heart disease uncouples endothelial nitric oxide synthase.

  2014cites this paper
• The Ebbs and Flows in the Development of Cholesterol‐Lowering Drugs: Prospects for the Future

  2014cites this paper
• Clinical Strategies for Managing Dyslipidemias

  2014cites this paper
• Building an Integrated Early Clinical Development Platform to Improve the Path to Proof of Concept

  2014cites this paper
• Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

  2014cites this paper
• Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

  2014cites this paper
• Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis

  2014cites this paper
• An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias

  2014cites this paper
• Aldosterone Increases Early Atherosclerosis and Promotes Plaque Inflammation Through a Placental Growth Factor‐Dependent Mechanism

  2013cites this paper
• Inhibitory CETP — czy nowe leki mają szansę zrewolucjonizować farmakoterapię miażdżycy?

  2013cites this paper
• Advances in Dyslipidemia

  2013cites this paper
• Mineralocorticoid Receptor–Mediated Vascular Insulin Resistance

  2013cites this paper
• Plaque regression and plaque stabilisation in cardiovascular diseases

  2013cites this paper
• Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond1

  2013cites this paper
• Cholesteryl Ester Transfer Protein Inhibitors in the Treatment of Dyslipidemia: A Systematic Review and Meta-Analysis

  2013cites this paper
• UvA-DARE ( Digital Academic Repository ) HDL cholesterol : atherosclerosis and beyond

  2013cites this paper
• Familial hypercholesterolaemia: new treatment options.

  2013cites this paper
• Is the Future of Statins Aligned with New Novel Lipid Modulation Therapies?

  2013cites this paper
• Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise.

  2013cites this paper
• HDL—is it too big to fail?

  2013cites this paper
• Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics.

  2013cites this paper
• Mineralocorticoid Receptors in Vascular Disease: Connecting Molecular Pathways to Clinical Implications

  2013cites this paper
• Carotid Intima-Media Thickness Testing as an Asymptomatic Cardiovascular Disease Identifier and Method for Making Therapeutic Decisions

  2013cites this paper
• Novel pharmacotherapies of familial hyperlipidemia.

  2013cites this paper
• Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins?

  2013cites this paper
• Utility of Biomarkers and Imaging in the Development of Drugs for the Treatment of Coronary

  2012cites this paper
• Challenge of Surrogate Endpoints

  2012cites this paper
• Reconstituted HDL Elicits Marked Changes in Plasma Lipids Following Single-Dose Injection in C57Bl/6 Mice

  2012cites this paper
• Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

  2012cites this paper
• Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis.

  2012cites this paper
• Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?

  2012cites this paper
• Lipid Lowering in Coronary Artery Disease

  2012cites this paper
• Working together in cardiovascular prevention: the common mission of the European Heart Journal and the European Journal of Preventive Cardiology

  2012cites this paper
• De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?

  2012cites this paper
• On-and Off-Target Pharmacology of Torcetrapib

  2012cites this paper
• Safety of CETP inhibition

  2012influential citation
• New lipid‐lowering drugs: an update

  2012cites this paper
• Phase 0 study of the inhibition of cholesteryl ester transfer protein activity by JNJ-28545595 in plasma from normolipidemic and dyslipidemic humans.

  2012cites this paper
• Mineralocorticoid receptors in vascular function and disease.

  2012cites this paper
• Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges

  2012cites this paper
• New Horizons for Cholesterol Ester Transfer Protein Inhibitors

  2012cites this paper
• Drugs targeting high-density lipoprotein cholesterol for coronary artery disease management.

  2012cites this paper
• Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases

  2012cites this paper
• Anacetrapib: hope for CETP inhibitors?

  2011cites this paper
• Emerging options in the treatment of dyslipidemias: a bright future?

  2011cites this paper
• Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology.

  2011cites this paper
• Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease.

  2011cites this paper
• Systems Modeling Applied to Candidate Biomarker Identification

  2011cites this paper
• Hypercholesterolemia: chemical aspect of approach.

  2011cites this paper
• Dalcetrapib: turning the tide for CETP inhibition?

  2011cites this paper
• Circulating plasma cholesteryl ester transfer protein activity and blood pressure tracking in the community

  2011cites this paper
• Characterization, Modes of Synthesis, and Pleiotropic Effects of Hypocholesterolemic Compounds – A Review

  2011cites this paper
• CETP expression reverses the reconstituted HDL-induced increase in VLDL

  2011cites this paper
• Utility of Atherosclerosis Imaging in the Evaluation of High-Density Lipoprotein–Raising Therapies

  2011cites this paper
• High-density lipoprotein cholesterol in diabetes: is higher always better?

  2011cites this paper
• The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease

  2011cites this paper
• Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.

  2011cites this paper
• Aldosterone Regulates Vascular Gene Transcription via Oxidative Stress–Dependent and –Independent Pathways

  2011cites this paper
• Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.

  2011cites this paper
• Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation

  2011cites this paper
• The DEFINE study: a bright future for CETP inhibitors?

  2011cites this paper
• Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling

  2011cites this paper
• Imaging of atherosclerosis.

  2011cites this paper
• Carotid Intima-Media Thickness Measurement: A Suitable Alternative for Cardiovascular Risk?

  2011cites this paper
• Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels

  2010cites this paper